Biotechnology sector-related exchange traded funds were in a bright spot on Friday after Bristol Myers Squibb Co. (NYSE: BMY) said it will acquire drug developers Turning Point Therapeutics (NasdaqGS: TPTX). Among the best performing non-leveraged ETFs of Friday, the SPDR S&P Biotech ETF...